Segment Information, EBITDA, Reconciling Items (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Unallocated costs [Abstract]
Impairment Charges And Gain Loss On Sale Of Assets		$ (2)	$ 3
Stock-based compensation		19	21
Restructuring And Other Special Items	[1]	9	8
Payments for (Proceeds from) Businesses and Interest in Affiliates	[2]	0	1
Other (income)/expense, net	[3]	(25)	(9)
Non Allocated Corporate Costs Net		36	16
Segment Reporting Information Unallocated Expense	[4]	$ 87	$ 56

[1] Restructuring and other special items during the three months ended September 30, 2022 include (i) transaction costs associated with the Metrics Contracts Services (“Metrics”) acquisition and (ii) warehouse exit costs for a product the Company no longer manufactures in its respiratory and specialty platform. Restructuring and other special items during the three months ended September 30, 2021 include (i) transaction and integration costs associated with the Delphi Genetics SA, Hepatic Cell Therapy Support SA, and RheinCell Therapeutics GmbH acquisitions (ii) transaction costs associated with the Bettera Holdings, LLC acquisition, and (iii) restructuring costs associated with the closure of the Company's facility in Bolton, U.K.

[2] Gain on sale of subsidiary for the three months ended September 30, 2021 was due to the sale of the facility in Woodstock, Illinois and the associated business

[3] Other expense, net during the three months ended September 30, 2022 includes foreign currency remeasurement losses/gains.Other expense, net during the three months ended September 30, 2021 includes financing charges related to the Company’s Incremental Term B-3 Loans and foreign currency remeasurement losses/gains.

[4] Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: